100 Migraine Drugs, A to Z: nebivolol

February 10, 2020

Nebivolol (Bystolic) is one of the newer, third generation beta-blockers, drugs used for the treatment of high blood pressure as well as migraine headaches. In Europe, it’s been in use for over 20 years.

In addition to beta-blockade, it may have additional beneficial effects on endothelium (blood vessel lining). It may also improve glucose metabolism by improving insulin sensitivity and other functions.

Nebivolol has the advantage of having fewer side effects than other beta blockers. including lower rates of fatigue and shortness of breath.

The majority of migraine sufferers are young women, many of who have low blood pressure, which predisposes them to side effects from beta blockers.

However, in the US, nebivolol is relatively expensive ($160 for one month supply) since it is not yet available in a generic form. Many insurers will not pay for it unless the patient cannot tolerate the widely used and inexpensive beta blockers such as propranolol, metoprolol, or atenolol.

Written by
Alexander Mauskop, MD
Continue reading
May 6, 2026
Alternative Therapies
New Research on Brain Excitability and TMS Treatment for Migraine
New research shows how the brain dynamically regulates excitability in real time—and why this matters for transcranial magnetic stimulation (TMS) as a treatment for migraine.
Read article
April 20, 2026
Can the Air You Breathe and the Weather Outside Trigger Your Migraines?
A major new study of over 7,000 migraine patients tracked two decades of air pollution, temperature, and humidity data, and found that the environment isn't just a background player. It's an active trigger.
Read article
April 17, 2026
Research
Not All Young Children Just “Bounce Back” from Concussion
A new study challenges the belief that young children quickly recover from concussions, showing that symptoms can persist for months and highlighting the importance of early evaluation and care.
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe